Chidozie Ugwumba - 16 Jun 2023 Form 4 Insider Report for Clene Inc. (CLNN)

Signature
/s/Chidozie Ugwumba
Issuer symbol
CLNN
Transactions as of
16 Jun 2023
Net transactions value
+$6,000,000
Form type
4
Filing time
08 Sep 2023, 16:33:35 UTC
Previous filing
08 Jun 2023
Next filing
02 Oct 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CLNN Common Stock Purchase $6,000,000 +7,500,000 +136% $0.8000 13,018,908 16 Jun 2023 By Symbiosis II, LLC F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CLNN Warrants (Right to buy) Award +7,500,000 7,500,000 16 Jun 2023 Common Stock 7,500,000 $1.50 By Symbiosis II, LLC F1, F2
transaction CLNN Warrants (Right to buy) Award +7,500,000 7,500,000 16 Jun 2023 Common Stock 7,500,000 $1.10 By Symbiosis II, LLC F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price for each Unit is $0.80; one Unit consists of one share of Common Stock of Clene, one Tranche A Warrant and one Tranche B Warrant.
F2 The reporting person purchased a unit consisting of one share of Common Stock of Clene Inc., one Tranche A Warrant, and one Tranche B Warrant. The Tranche B Warrant is for 7,500,000 shares of Common Stock of Clene Inc. at an exercise price of $1.50 per share. The Tranche B Warrant will expire on the earlier of (a) June 16, 2030, or (b) 60 days after the Food and Drug Administration accepts a New Drug Application from Clene Inc.
F3 The reporting person purchased a unit consisting of one share of Common Stock of Clene Inc., one Tranche A Warrant, and one Tranche B Warrant. The Tranche A Warrant is for 7,500,000 shares of Common Stock of Clene Inc. at an exercise price of $1.10 per share. The Tranche A Warrant will expire on the earlier of (a) June 16, 2026, or (b) 60 days after the Food and Drug Administration accepts a New Drug Application from Clene Inc.